Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
stocks
Here’s how to value a share
stocks
How to avoid dividend disaster
stocks
GyG punished by market after solid earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,245.00 | 45.00 | -0.48% |
CAC 40 | 7,839.02 | 130.67 | -1.64% |
DAX 40 | 24,261.59 | 101.50 | -0.42% |
Dow JONES (US) | 45,447.23 | 184.51 | -0.40% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,829.91 | 725.30 | 2.89% |
NASDAQ | 21,559.10 | 62.57 | 0.29% |
Nikkei 225 | 42,807.82 | 197.65 | 0.46% |
NZX 50 Index | 13,079.50 | 114.57 | -0.87% |
S&P 500 | 6,464.13 | 2.78 | -0.04% |
S&P/ASX 200 | 8,972.40 | 52.00 | -0.58% |
SSE Composite Index | 3,883.56 | 57.80 | 1.51% |